MX2017005642A - Anticuerpos anti-angiopoyetina 2 (ang2) y metodos de uso. - Google Patents

Anticuerpos anti-angiopoyetina 2 (ang2) y metodos de uso.

Info

Publication number
MX2017005642A
MX2017005642A MX2017005642A MX2017005642A MX2017005642A MX 2017005642 A MX2017005642 A MX 2017005642A MX 2017005642 A MX2017005642 A MX 2017005642A MX 2017005642 A MX2017005642 A MX 2017005642A MX 2017005642 A MX2017005642 A MX 2017005642A
Authority
MX
Mexico
Prior art keywords
methods
ang2 antibodies
hvr
seq
amino acid
Prior art date
Application number
MX2017005642A
Other languages
English (en)
Inventor
Georges Guy
Moelleken Joerg
Kettenberger Hubert
Thomas Regula Joerg
Michael Huelsmann Peter
Dengl Stefan
Molhoj Michael
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2017005642A publication Critical patent/MX2017005642A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

En el presente documento se informa de anticuerpos anti-ANG2. Un anticuerpo anti-ANG2 específico comprende (a) un RHV-H1 que comprende la secuencia de aminoácidos SEC ID N° 29, (b) un RHV-H2 que comprende la secuencia de aminoácidos SEC ID N° 30, y (c) un RHV-H3 que comprende la secuencia de aminoácidos SEC ID N° 32.µ.
MX2017005642A 2014-11-10 2015-11-06 Anticuerpos anti-angiopoyetina 2 (ang2) y metodos de uso. MX2017005642A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14192524 2014-11-10
PCT/EP2015/075876 WO2016075035A1 (en) 2014-11-10 2015-11-06 Anti-ang2 antibodies and methods of use

Publications (1)

Publication Number Publication Date
MX2017005642A true MX2017005642A (es) 2017-07-24

Family

ID=51868115

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017005642A MX2017005642A (es) 2014-11-10 2015-11-06 Anticuerpos anti-angiopoyetina 2 (ang2) y metodos de uso.

Country Status (14)

Country Link
US (1) US10538585B2 (es)
EP (1) EP3218398A1 (es)
JP (2) JP2017534644A (es)
KR (1) KR20170082594A (es)
CN (1) CN107001456A (es)
AR (1) AR102595A1 (es)
AU (1) AU2015345321A1 (es)
BR (1) BR112017009790A2 (es)
CA (1) CA2963606A1 (es)
IL (1) IL251477A0 (es)
MX (1) MX2017005642A (es)
SG (1) SG11201703458UA (es)
TW (1) TW201630935A (es)
WO (1) WO2016075035A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170080584A (ko) 2014-11-10 2017-07-10 에프. 호프만-라 로슈 아게 이중특이적 항체 및 안과학에서 이의 사용 방법
CA2963719A1 (en) 2014-11-10 2016-05-19 F. Hoffmann-La Roche Ag Anti-il-1beta antibodies and methods of use
CN107148429B (zh) 2014-11-10 2021-12-03 豪夫迈·罗氏有限公司 抗-pdgf-b抗体和使用方法
EP3728327A1 (en) 2017-12-22 2020-10-28 F. Hoffmann-La Roche AG Depletion of light chain mispaired antibody variants by hydrophobic interaction chromatography
WO2019164219A1 (en) * 2018-02-20 2019-08-29 Institute For Basic Science Anti-angiopoietin-2 antibodies and uses thereof
KR102497171B1 (ko) 2018-02-20 2023-02-08 기초과학연구원 항-안지오포이에틴-2(Ang2) 항체 및 그의 용도
CN115734971A (zh) 2020-06-22 2023-03-03 信达生物制药(苏州)有限公司 抗ang-2抗体及其用途
EP4201957A1 (en) * 2020-08-19 2023-06-28 Pharmabcine Inc. Modified antibody and method for manufacturing same
CN115772544B (zh) * 2021-09-06 2024-04-26 合肥星眸生物科技有限公司 抗vegf-a和ang-2的aav载体
CN117820490A (zh) * 2022-09-28 2024-04-05 科兴生物制药股份有限公司 Vegf和ang-2双特异性抗体及其应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935343A (en) 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
EP1481010A2 (en) 2002-02-28 2004-12-01 Eli Lilly And Company Anti-interleukin-1 beta analogs
PT1517921E (pt) * 2002-06-28 2006-09-29 Domantis Ltd Ligandos duplamente especificos com semi-vida no soro aumentada
ES2567198T3 (es) 2003-01-24 2016-04-20 Applied Molecular Evolution, Inc. Antagonistas de la IL-1 beta humana
WO2005087812A1 (en) 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for vegf/pdgf family of growth factors
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
AR059066A1 (es) * 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
CN101861168B (zh) 2007-05-07 2014-07-02 米迪缪尼有限公司 抗-icos抗体及其在***、移植和自身免疫病中的应用
US20090162359A1 (en) * 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
JO2913B1 (en) * 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
DK2293816T3 (da) 2008-06-06 2013-02-04 Xoma Technology Ltd Fremgangsmåder til behandling af reumatoid arthritis
RU2368359C1 (ru) 2008-07-22 2009-09-27 Государственное учреждение "УФИМСКИЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИНСТИТУТ ГЛАЗНЫХ БОЛЕЗНЕЙ" Академии наук Республики Башкортостан (УфНИИ ГБ АН РБ) Способ лечения возрастной макулярной дегенерации
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
US8133979B2 (en) * 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
AR080794A1 (es) 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
WO2012021773A1 (en) 2010-08-13 2012-02-16 Genentech, Inc. Antibodies to il-1beta and il-18, for treatment of disease
NZ607510A (en) 2010-09-10 2014-10-31 Apexigen Inc Anti-il-1 beta antibodies and methods of use
EP2686345B1 (en) 2011-03-16 2018-04-25 Amgen Inc. Fc variants
WO2013003606A1 (en) * 2011-06-29 2013-01-03 Amgen Inc. Predictive biomarker of survival in the treatment of renal cell carcinoma
US9163070B2 (en) 2012-06-28 2015-10-20 Molecular Partners Ag Designed ankyrin repeat proteins binding to platelet-derived growth factor
HUE056217T2 (hu) * 2012-07-13 2022-02-28 Roche Glycart Ag Bispecifikus anti-VEGF/anti-ANG-2 antitestek és ezek alkalmazása szemészeti érbetegségek kezelésében
BR112015006363A2 (pt) * 2012-09-28 2017-08-08 Boehringer Ingelheim Int combinações farmacêuticas compreendendo ligantes angiopoietina-2/dll4 duplos e agentes anti-vegf-r
WO2014049100A1 (en) * 2012-09-28 2014-04-03 Boehringer Ingelheim International Gmbh Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf agents
MX2015005839A (es) 2012-11-08 2015-12-17 Clearside Biomedical Inc Metodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos.
CA2890483A1 (en) 2012-11-09 2014-05-15 Robert ARCH Platelet-derived growth factor b specific antibodies and compositions and uses thereof
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
PE20190920A1 (es) * 2013-04-29 2019-06-26 Hoffmann La Roche Anticuerpos modificados de union a fcrn humano y metodos de utilizacion
PE20160753A1 (es) * 2013-12-20 2016-08-01 Hoffmann La Roche Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40
RU2727639C2 (ru) * 2014-01-15 2020-07-22 Ф.Хоффманн-Ля Рош Аг Варианты fc-области с модифицированной способностью связываться с fcrn и с сохраненной способностью связываться с белком а
CA2963719A1 (en) 2014-11-10 2016-05-19 F. Hoffmann-La Roche Ag Anti-il-1beta antibodies and methods of use
CN107148429B (zh) 2014-11-10 2021-12-03 豪夫迈·罗氏有限公司 抗-pdgf-b抗体和使用方法
KR20170080584A (ko) * 2014-11-10 2017-07-10 에프. 호프만-라 로슈 아게 이중특이적 항체 및 안과학에서 이의 사용 방법
WO2016209972A1 (en) * 2015-06-26 2016-12-29 Amgen Inc. Biomarker of survival in the treatment of renal cell carcinoma with a vegfr inhibitor and an ang2 inhibitor
KR20200013231A (ko) * 2017-06-02 2020-02-06 베링거 인겔하임 인터내셔날 게엠베하 항암 조합 요법

Also Published As

Publication number Publication date
CN107001456A (zh) 2017-08-01
BR112017009790A2 (pt) 2017-12-19
IL251477A0 (en) 2017-05-29
CA2963606A1 (en) 2016-05-19
US20170247441A1 (en) 2017-08-31
JP2017534644A (ja) 2017-11-24
TW201630935A (zh) 2016-09-01
JP2021050229A (ja) 2021-04-01
SG11201703458UA (en) 2017-05-30
AU2015345321A1 (en) 2017-04-20
KR20170082594A (ko) 2017-07-14
US10538585B2 (en) 2020-01-21
EP3218398A1 (en) 2017-09-20
AR102595A1 (es) 2017-03-08
WO2016075035A1 (en) 2016-05-19

Similar Documents

Publication Publication Date Title
MX2017005642A (es) Anticuerpos anti-angiopoyetina 2 (ang2) y metodos de uso.
MX2017005987A (es) Anticuerpos anti-interleucina(il)-1beta y metodos de uso.
ES2685424T3 (es) Anticuerpos anti-Jagged1 y procedimientos de uso
NZ762843A (en) Anti-egfr antibodies and antibody drug conjugates
PH12017500915A1 (en) Cd47 antibodies, methods, and uses
PE20161571A1 (es) Anticuerpos anti-ox40 y metodos de uso
AR096364A1 (es) Anticuerpos receptores de antitransferina y métodos de uso
EA201990293A1 (ru) Мультиспецифичные антитела против cd40 и cd137
PE20180317A1 (es) Anticuerpos anti-tau y metodos de uso
AR110321A1 (es) Anticuerpos antitau y métodos de uso
SG10201914126RA (en) Anti-ox40 antibodies and their uses
PH12018500708A1 (en) Humanized anti-human cd19 antibodies and methods of use
AR102918A1 (es) Anticuerpos anti-cd79b y métodos de uso
AR096687A1 (es) Anticuerpos anti-fcrh5
MX2016012124A (es) Anticuerpos contra glicopeptidos inmunogenicos, composicion que los comprende y usos de estos.
NZ741067A (en) Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
NZ761537A (en) Anti-human ox40l antibodies, uses & methods
PH12016501937A1 (en) Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage
PE20181402A1 (es) Anticuerpos anti-c5 y metodos de uso
NZ626520A (en) Anti-lrp5 antibodies and methods of use
AR099855A1 (es) Anticuerpos hemaglutinina del virus antiinfluenza b y métodos de uso
AR078377A1 (es) Anticuerpos anti-vegf-c (factor de crecimiento endotelial anti-vascular aislado c) y sus metodos de uso
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
MX2023006416A (es) Anticuerpos, usos y metodos.
WO2016057683A3 (en) Novel anti-nodal antibodies and methods of using same